Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
DIS3 like exosome 3'-5' exoribonuclease (DIS3L) is a cytoplasmic catalytic subunit of the multisubunit RNA exosome complex, exhibiting 3'-to-5' exoribonuclease activity that is essential for the degradation and processing of various RNA species. Unlike the related DIS3, which is primarily nuclear, DIS3L is restricted to the cytoplasm and collaborates with the exosome core to degrade unstable and normal mRNAs, thereby regulating cytoplasmic RNA turnover and protein synthesis. DIS3L plays a crucial role in embryonic development, with knockout studies demonstrating that its complete loss leads to embryonic lethality in mice. Mutations and dysregulation of DIS3L have been associated with cancer, including prostate cancer and Perlman syndrome. Despite its vital role in RNA metabolism, there are currently no known drugs directly targeting DIS3L, and its precise therapeutic utility remains under investigation[2][3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on DIS3 like exosome 3'-5' exoribonuclease (DIS3L).